CareDx, Inc. (CDNA) - Q3 2025 10-Q Summary
Business Context and Reporting Period
CareDx, Inc. is a precision medicine company focused on diagnostic solutions for transplant patients, offering testing services (AlloSure, AlloMap), products, and digital solutions. This report covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $100.1 million | $82.9 million | $271.4 million | $247.2 million |
| Net Income (Loss) | $1.7 million | ($10.6 million) | ($17.2 million) | ($35.1 million) |
| Operating Loss | ($0.2 million) | ($13.7 million) | ($24.7 million) | ($43.6 million) |
| Cash & Marketable Securities | $194.2 million | N/A | N/A | N/A |
| Debt | $0 | $0 | $0 | $0 |
| Accumulated Deficit | ($719.0 million) | N/A | N/A | N/A |
Note: Q3 2024 figures reflect immaterial corrections to prior period financial statements regarding stock-based compensation.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 21% year-over-year in Q3 2025, driven by a 19% increase in testing services revenue and a 30% increase in patient and digital solutions revenue.
- Profitability: The company reported a net income of $1.7 million in Q3 2025, a significant improvement from a net loss of $10.6 million in Q3 2024. Operating loss narrowed from $13.7 million to $0.2 million.
- Expense Management: General and administrative expenses decreased 10% year-over-year, primarily due to a $6.4 million reduction in stock-based compensation. Research and development expenses decreased 4%.
- Share Repurchases: The company repurchased 5.0 million shares for $75.6 million during the first nine months of 2025 under two authorized programs.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items: The company recorded a litigation settlement expense of approximately $5.7 million for the nine months ended September 30, 2025, related to a securities class action settlement. Additionally, a one-time impairment charge of $2.3 million was recorded related to an intangible asset.
- Internal Controls: A material weakness in internal control over financial reporting, identified in the 2024 fiscal year, remains unremediated as of September 30, 2025. Management is actively implementing remediation plans.
- Legal Proceedings:
- Natera Litigation: The Third Circuit affirmed the District Court's findings on liability and damages regarding false advertising claims. However, the Court previously invalidated Natera's patents asserted against CareDx. Natera has appealed the invalidation.
- Securities Class Action: A settlement of approximately $20.25 million was preliminarily approved by the court, with a fairness hearing scheduled for December 2, 2025.
- Reimbursement Risks: Approximately 32% of Q3 2025 revenue was derived from Medicare. The company faces potential reimbursement rate adjustments for its AlloSure tests under new CPT codes effective January 1, 2026.
- Outlook: Management believes existing cash and expected cash from operations will be sufficient to meet requirements for the next 12 months. No specific financial guidance was provided in this filing.
Investor Verification Checklist
- Remediation of Material Weakness: Verify the progress of remediation efforts for the internal control weakness regarding complex transactions and stock-based compensation.
- Medicare Reimbursement Rates: Monitor the finalization of reimbursement rates for PLA Code 0540U, expected to be listed on the Clinical Laboratory Fee Schedule starting January 1, 2026.
- Legal Settlement Finalization: Confirm the final court approval of the $20.25 million securities class action settlement and the status of the Natera patent appeal.
- Share Repurchase Impact: Assess the impact of the $75.6 million in share repurchases on liquidity and future capital allocation.
- Revenue Mix: Track the sustainability of the 30% growth in patient and digital solutions revenue, which is a key diversification driver.